Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall MARD. The results were presented at the American Diabetes Association® (ADA) 82nd Scientific Sessions, June 3-7, 2022, in New Orleans. MARD is considered the simplest measurement of sensor accuracy and represents the difference between a CGM system's glucose readings and a reference blood glucose measurement.

The lower the MARD, the more accurate the CGM system. The multi-center study evaluated the accuracy of the FreeStyle Libre system in people with type 1 or type 2 diabetes, aged 4 or older, who were on insulin therapy. By age group, MARD values were 7.6% for adults (people ages 18 and up) and 8.7% for children ages 6-17.

For children aged 4-5 years old, MARD value was 10.1%. Other notable findings presented at ADA: FreeStyle Libre system helps prevent therapeutic inertia: Getting glycemic levels under control earlier can lead to better outcomes, including a reduction in long-term vascular complications. An analysis of retrospective data collected over 24 months from more than 370,000 patients with type 2 diabetes in Canada shows that insights from FreeStyle Libre data helped clinicians make earlier decisions or adjustments to type 2 diabetes treatments versus making decisions based on conventional blood glucose monitoring (BGM).

A comparative study suggests that new Glucose Pattern Insights report in LibreView helps primary care providers identify and treat hypoglycemia events that are missed when using standardized reports: Powered by LibreView the Glucose Pattern Insights report is a new CGM-based tool that was developed to identify patterns of poor glycemic control and offer considerations for the clinician.